⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Center for Genetic Engineering and Biotechnology (CIGB) and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
The Center for Genetic Engineering and Biotechnology (CIGB) is a prominent Cuban research and development institution founded in 1986. It operates as a high-tech enterprise under the BioCubaFarma umbrella, focusing on the research, development, production, and commercialization of biopharmaceuticals, vaccines, and diagnostic tools for human and veterinary use.
CIGB is known for its work in genetic engineering, monoclonal antibodies, and recombinant proteins. Its portfolio includes significant products such as Heberprot-P (for diabetic foot ulcers), various interferons, and COVID-19 vaccines like Abdala and Mambisa. The center maintains extensive facilities in Havana and other provinces, adhering to international standards for biomanufacturing.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Vaccines and Recombinant Therapeutics
SIZE & FINANCIALS
Employees:1001-5000
Founded:1986
Ownership:government
Status:operating
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Recombinant proteins, Monoclonal antibodies, Vaccines, Peptides
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:BioCubaFarma
Subsidiaries:CIGB Mariel S.A.
Key Partnerships:BioCubaFarma (Parent organization), Heber Biotec S.A. (Commercialization partner)
COMPETITION
Position:Leader
LEADERSHIP
Key Executives:
Gerardo Guillen - Director of Biomedical Research
Verena Muzio - Director of Clinical Research
LINKS
Website:cigb.edu.cu
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Center for Genetic Engineering and Biotechnology (CIGB). The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.